We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ocugen (OCGN) is expected to provide updates regarding the developmental program of its lead candidate, OCU400, for two rare retinal diseases in the first-quarter earnings release.
Fusion (FUSN) is expected to provide updates regarding the developmental program of its lead candidate, FPI-2265, for prostate cancer in the first-quarter earnings release.
Bristol-Myers' (BMY) first-quarter 2024 loss is narrower than estimated. Sales surpass the consensus mark on the back of Eliquis, Reblozyl and Opdualag's encouraging performance. However, Opdivo sales disappoint.
Zoetis' (ZTS) higher companion animal product sales are expected to have driven revenues in the first quarter of 2024 in both the United States and International segments.
Incyte's (INCY) first-quarter 2024 revenues are likely to have been driven by the U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.
Vertex (VRTX) signs a collaboration agreement with TreeFrog to utilize the latter's C-Stem technology in order to optimize the production of its T1D cell therapies.
Immunovant's (IMVT) late-stage studies evaluating its lead candidate, batoclimab, for various autoimmune indications are progressing well. Several data readouts are expected in 2024 and 2025.
Vertex (VRTX) begins rolling NDA submission for its investigational non-opioid candidate, suzetrigine, for acute pain management. The submission is expected to be completed in second-quarter 2024.
Bio-Path (BPTH) gains 30% on encouraging developmental updates from the early-stage study of its investigational candidate, BP1002, to treat acute myeloid leukemia patients.
Roche (RHHBY) has won FDA approval for Alecensa as an adjuvant treatment, following tumor resection for patients with ALK-positive non-small cell lung cancer.
DiaMedica (DMAC) rises 10% as it doses the first patient in the relaunch of its pivotal study evaluating the lead candidate, DM199, to treat acute ischemic stroke.
Intra-Cellular (ITCI) jumps 23% after achieving key goals in the late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
biotechnology: Archive
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Ocugen (OCGN) is expected to provide updates regarding the developmental program of its lead candidate, OCU400, for two rare retinal diseases in the first-quarter earnings release.
ALNYNegative Net Change SRPTPositive Net Change ARGXPositive Net Change OCGNPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Gilead (GILD) reports narrower-than-expected loss in the first quarter. Its sales beat estimates on higher HIV, Oncology and Liver Disease sales.
GILDPositive Net Change ANIPPositive Net Change ADMAPositive Net Change XLOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Fusion (FUSN) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Fusion (FUSN) is expected to provide updates regarding the developmental program of its lead candidate, FPI-2265, for prostate cancer in the first-quarter earnings release.
AZNPositive Net Change MRKPositive Net Change SRPTPositive Net Change FUSNPositive Net Change
biotechnology biotechs earnings medical oncology-screening pharmaceuticals
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
by Zacks Equity Research
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
BIIBPositive Net Change BMYPositive Net Change VRTXNegative Net Change INCYPositive Net Change
biotechnology biotechs
New Strong Sell Stocks for April 26th
by Zacks Equity Research
AMPH, BCML and DHC have been added to the Zacks Rank #5 (Strong Sell) List on April 26, 2024.
AMPHPositive Net Change BCMLPositive Net Change DHCPositive Net Change
biotechnology
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
by Zacks Equity Research
Biogen (BIIB) and Bristol Myers (BMY) are in focus following Q1 earnings announcement.
BIIBPositive Net Change BMYPositive Net Change VRTXNegative Net Change INCYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Bristol-Myers' (BMY) first-quarter 2024 loss is narrower than estimated. Sales surpass the consensus mark on the back of Eliquis, Reblozyl and Opdualag's encouraging performance. However, Opdivo sales disappoint.
BMYPositive Net Change PFEPositive Net Change ANIPPositive Net Change ADMAPositive Net Change
biotechnology biotechs earnings pharmaceuticals
Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis' (ZTS) higher companion animal product sales are expected to have driven revenues in the first quarter of 2024 in both the United States and International segments.
ALNYNegative Net Change SRPTPositive Net Change ZTSPositive Net Change BLUEPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Best Momentum Stocks to Buy for April 25th
by Zacks Equity Research
TXO, PEPG and ERO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 25, 2024.
EROPositive Net Change PEPGPositive Net Change TXOPositive Net Change
biotechnology
Should Eli Lilly (LLY) Be in Your Portfolio Ahead of Q1 Earnings?
by Kinjel Shah
Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.
NVOPositive Net Change LLYPositive Net Change ADMAPositive Net Change
biotechnology
What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
by Ahan Chakraborty
Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.
SNYNegative Net Change BMYPositive Net Change MRKPositive Net Change GILDPositive Net Change ABBVNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Royal Gold (RGLD)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
RGLDPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Incyte (INCY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Incyte's (INCY) first-quarter 2024 revenues are likely to have been driven by the U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.
NVSNegative Net Change INCYPositive Net Change SRPTPositive Net Change CTMXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies
by Zacks Equity Research
Vertex (VRTX) signs a collaboration agreement with TreeFrog to utilize the latter's C-Stem technology in order to optimize the production of its T1D cell therapies.
VRTXNegative Net Change ADMAPositive Net Change FGENPositive Net Change ANVSPositive Net Change
biotechnology biotechs cell-therapy medical pharmaceuticals
Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?
by Zacks Equity Research
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports first-quarter 2024 results.
GILDPositive Net Change ONCYPositive Net Change FATENegative Net Change OMGANegative Net Change
biotechnology biotechs medical pharmaceuticals
Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know
by Zacks Equity Research
Investors are likely to focus on Opdivo's demand, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) posts Q1 results.
BMYPositive Net Change ONCYPositive Net Change FATENegative Net Change OMGANegative Net Change
biotechnology biotechs earnings pharmaceuticals
Here's Why You Should Add Immunovant (IMVT) to Your Portfolio
by Zacks Equity Research
Immunovant's (IMVT) late-stage studies evaluating its lead candidate, batoclimab, for various autoimmune indications are progressing well. Several data readouts are expected in 2024 and 2025.
ADMAPositive Net Change FGENPositive Net Change IMVTNegative Net Change ANVSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug
by Zacks Equity Research
Vertex (VRTX) begins rolling NDA submission for its investigational non-opioid candidate, suzetrigine, for acute pain management. The submission is expected to be completed in second-quarter 2024.
VRTXNegative Net Change ADMAPositive Net Change FGENPositive Net Change ANVSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study
by Zacks Equity Research
Bio-Path (BPTH) gains 30% on encouraging developmental updates from the early-stage study of its investigational candidate, BP1002, to treat acute myeloid leukemia patients.
BPTHPositive Net Change ADMAPositive Net Change FGENPositive Net Change ANVSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Roche (RHHBY) Alecensa Wins FDA Nod for Label Expansion
by Zacks Equity Research
Roche (RHHBY) has won FDA approval for Alecensa as an adjuvant treatment, following tumor resection for patients with ALK-positive non-small cell lung cancer.
RHHBYPositive Net Change LGNDPositive Net Change ANIPPositive Net Change ADMAPositive Net Change
biotechnology medical pharmaceuticals
Novartis (NVS) to Report Q1 Earnings: What to Expect?
by Ekta Bagri
Novartis (NVS) key drugs Entresto, Kisqali and Pluvicto are likely to have fueled its top and bottom-line numbers in the first quarter.
NVSNegative Net Change BMRNNegative Net Change ONCYPositive Net Change FATENegative Net Change
biotechnology earnings medical pharmaceuticals
Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success
by Zacks Equity Research
Regeneron (REGN) and Sage Therapeutics (SAGE) are in focus on regulatory and pipeline updates.
REGNNegative Net Change GSKPositive Net Change ITCIPositive Net Change SAGEPositive Net Change NMRAPositive Net Change
biotechnology biotechs pharmaceuticals
DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch
by Zacks Equity Research
DiaMedica (DMAC) rises 10% as it doses the first patient in the relaunch of its pivotal study evaluating the lead candidate, DM199, to treat acute ischemic stroke.
ADMAPositive Net Change FGENPositive Net Change DMACPositive Net Change ANVSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Intra-Cellular (ITCI) Up as Depression Drug Meets Study Goals
by Zacks Equity Research
Intra-Cellular (ITCI) jumps 23% after achieving key goals in the late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
ITCIPositive Net Change ADMAPositive Net Change FGENPositive Net Change ANVSPositive Net Change
biotechnology biotechs medical pharmaceuticals
bluebird (BLUE) Underperforms Industry YTD Amid Challenges
by Zacks Equity Research
bluebird (BLUE) plunges 25% year to date as it struggles to fuel the growth of its complex and expensive gene therapies.
VRTXNegative Net Change BLUEPositive Net Change ADMAPositive Net Change CRSPPositive Net Change
biotechnology biotechs pharmaceuticals